Treatment with a MMP9-blocking antibody did not affect the tumor growth of subcutaneously implanted PDAC cells, but did enhance gemcitabine and nab-paclitaxel sensitivity when PDAC cells were injected into the peritoneal cavity [87]. Here, MMP9 is linked to neoplasm.